Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?

Endokrynologia Polska

Volumn 60, Issue 1, 2009, Pages 20-24

  Stelmachowska Banaś, Maria ^a   Zdunowski, Piotr ^a   Zgliczyński, Wojciech ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Acromegaly; Diabetes mellitus; Impaired fasting glucose; Impaired glucose tolerance; Insulin resistance

Indexed keywords

INSULIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLUCOSE INTOLERANCE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE;

ACROMEGALY; ADULT; AGE OF ONSET; AGED; AREA UNDER CURVE; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; GLUCOSE INTOLERANCE; GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLAND; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 64149119864     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Nabarro JDN. Acromegaly. Clin Endorinol (Oxf) 1987; 26: 481-512.
2. Wright AD et al. Mortality in acromegaly. QJ Med 1970; 153: 1-16.
3. Bengtsson B et al. Epidemiology and long term survival in acromegaly. Acta Med Scand 1988; 223: 327-335.
4. Orme SM, McNally RJ, Cartwright RA et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998; 83: 2730-2734.
5. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998; 352: 1445-1461.
6. López-Velasco R, Escobar-Morreale HF, Vega B et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997; 82: 1047-1053.
7. Colao A, Baldelli R, Marzullo P et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-199.
8. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 2001; 34: 1429-1433.
9. Biering H, Knappe G, Gerl H et al. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Aust 2000; 27: 27-31.
10. Kasayama S, Otsuki M, Takagi M et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000; 52: 549-555.
11. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetol 1985; 28: 412-419.
12. Colao A, Ferone D, Marzullo P et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Rev 2004; 25: 102-152.
13. Wass JA, Cudworth AG, Bottazzo GF et al. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12: 53-59.
14. Nabarro JDN Acromegaly. Clin Endocrinol (Oxf) 1987; 26: 481-512.
15. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
16. Szybiński Z. Polskie Wieloośrodkowe Badania nad Epidemiologia Cukrzycy (PWBEC) - 1998-2000. Pol Arch Med Wewn 2001; 106: 751.